Browse by author
Lookup NU author(s): Professor Alan Boddy
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Paclitaxel poliglumex (Xyotax™) is a glutamic acid polymer formulation of paclitaxel in which the active drug is covalently bound with a loading of approximately 38% by weight of the total polymer. Preclinical studies suggested antitumor activity superior to that of equitoxic doses of native paclitaxel, as well as enhanced tumor delivery and retention of the active drug. Subsequent clinical evaluation indicated some activity, but at the expense of neurotoxicity. Clinical evaluation is ongoing, especially in lung cancer, with a specific indication that women with normal or high levels of estrogen may be particularly responsive to this drug. Copyright © 2007 Prous Science.
Author(s): Boddy, A. V.
Publication type: Article
Publication status: Published
Journal: Drugs of the Future
Print publication date: 01/09/2007
ISSN (print): 0377-8282